Edwards Lifesciences Corporation (NYSE:EW) had its price target trimmed by Deutsche Bank AG from $122.00 to $115.00 in a research note issued to investors on Thursday, October 26th. The brokerage currently has a hold rating on the medical research company’s stock.
A number of other equities research analysts have also issued reports on the company. BMO Capital Markets reiterated a buy rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. William Blair restated an outperform rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. Barclays PLC raised their price objective on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an equal weight rating in a research note on Thursday, July 27th. Canaccord Genuity restated a buy rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Finally, Zacks Investment Research upgraded Edwards Lifesciences Corporation from a hold rating to a buy rating and set a $130.00 target price for the company in a research report on Tuesday, July 18th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $125.17.
Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at $105.15 on Thursday. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The stock has a market capitalization of $22,250.00, a price-to-earnings ratio of 28.77, a PEG ratio of 1.86 and a beta of 0.46. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76.
Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.68 earnings per share. sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Given New $115.00 Price Target at Deutsche Bank AG” was posted by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://baseballnewssource.com/markets/edwards-lifesciences-corporation-ew-price-target-cut-to-115-00-by-analysts-at-deutsche-bank-ag/1738371.html.
In other news, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $111.81, for a total value of $2,119,917.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $112.15, for a total value of $594,395.00. The disclosure for this sale can be found here. Insiders have sold 139,580 shares of company stock worth $15,143,994 over the last 90 days. Corporate insiders own 2.13% of the company’s stock.
A number of large investors have recently bought and sold shares of EW. ETF Managers Group LLC acquired a new position in Edwards Lifesciences Corporation during the 2nd quarter worth $112,000. Shine Investment Advisory Services Inc. acquired a new position in Edwards Lifesciences Corporation during the 2nd quarter worth $126,000. Cornerstone Advisors Inc. lifted its holdings in Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares in the last quarter. Alexandria Capital LLC lifted its holdings in Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new position in Edwards Lifesciences Corporation during the 2nd quarter worth $140,000. 82.17% of the stock is currently owned by hedge funds and other institutional investors.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with our FREE daily email newsletter.